Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.

Chris Fegan,Alexey V. Danilov,Daniel J. Hodson,Gilles Salles,Alexander Starodub,Siddhartha Mitra,Yingsi Yang,Harriet S. Walter,Franck Morschhauser

Preliminary results of a phase Ib study of GS-4059 in combination with entospletinib in patients with B-cell malignancies.

2017

Chris Fegan
Alexey V. Danilov
Daniel J. Hodson
Gilles Salles
Alexander Starodub
Siddhartha Mitra
Yingsi Yang
Harriet S. Walter
Franck Morschhauser

7518Background: GS-4059 (ONO-4059) selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK) and entospletinib selectively inhibits spleen tyrosine kinase (SYK). Methods: This ongoing ph...

Keywords:

Entospletinib
Oncology
Pathology
Internal medicine
B cell
Medicine
Tyrosine kinase
in patient
Cancer research
Syk
Bruton's tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations